CD30-targeted antibody therapy

Current Opinion in Oncology

Volumn 23, Issue 6, 2011, Pages 587-593

  Younes, Anas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

anaplastic large cell lymphoma; antibody drug conjugate; auristatin; Hodgkin's lymphoma; SGN 35

Indexed keywords

AFM 13; ANTIBODY; ANTIBODY CONJUGATE; BRENTUXIMAB VEDOTIN; CD30 ANTIBODY; CD30 ANTIGEN; CD30 LIGAND; HISTONE DEACETYLASE INHIBITOR; IRATUMUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD30; MONOCLONAL ANTIBODY KI 4 I 131; RADIOIMMUNOCONJUGATE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CLASSICAL HODGKIN LYMPHOMA; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; FATIGUE; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; LARGE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; PERIPHERAL T CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN STRUCTURE; RETREATMENT; REVIEW; SENSORY NEUROPATHY; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD30; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOCONJUGATES; NEOPLASMS;

EID: 80054111050     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32834bb8a7     Document Type: Review

References (52)

1. Schwab U, Stein H, Gerdes J, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982; 299:65-67. (Pubitemid 12049770)
2. Durkop H, Latza U, Hummel M, et al. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992; 68:421-427.
3. Fonatsch C, Latza U, Durkop H, et al. Assignment of the human CD30 (Ki-1) gene to 1p36. Genomics 1992; 14:825-826.
4. Smith CA, Gruss HJ, Davis T, et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993; 73:1349-1360. (Pubitemid 23201148)
5. Younes A, Carbone A. Clinicopathologic and molecular features of Hodgkin's lymphoma. Cancer Biol Ther 2003; 2:500-507.
6. Younes A, Carbone A. CD30/CD30 ligand and CD40/CD40 ligand in malignant lymphoid disorders. Int J Biol Markers 1999; 14:135-143. (Pubitemid 29495742)
7. Amakawa R, Hakem A, Kundig TM, et al. Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell 1996; 84:551-562.
8. DeYoung AL, Duramad O, Winoto A. The TNF receptor family member CD30 is not essential for negative selection. J Immunol 2000; 165:6170-6173.
9. Gaspal FM, Kim MY, McConnell FM, et al. Mice deficient in OX40 and CD30 signals lack memory antibody responses because of deficient CD4 T cell memory. J Immunol 2005; 174:3891-3896. (Pubitemid 40395961)
10. Gaspal F, Withers D, Saini M, et al. Abrogation of CD30 and OX40 signals prevents autoimmune disease in FoxP3-deficient mice. J Exp Med 2011; 208:1579-1584.
11. Kurts C, Carbone FR, Krummel MF, et al. Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature 1999; 398:341-344.
12. Lyons PA, Hancock WW, Denny P, et al. The NOD Idd9 genetic interval influences the pathogenicity of insulitis and contains molecular variants of Cd30, Tnfr2, and Cd137. Immunity 2000; 13:107-115.
13. Gruss HJ, Boiani N, Williams DE, et al. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 1994; 83:2045-2056. (Pubitemid 24112714)
14. Hirsch B, Hummel M, Bentink S, et al. CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells. Am J Pathol 2008; 172:510-520. (Pubitemid 351282036)
15. Mir SS, Richter BW, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood 2000; 96:4307-4312.
16. Croager EJ, Gout AM, Abraham LJ. Involvement of Sp1 and microsatellite repressor sequences in the transcriptional control of the human CD30 gene. Am J Pathol 2000; 156:1723-1731. (Pubitemid 30648881)
17. Buglio D, Mamidipudi V, Khaskhely NM, et al. The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism. Br J Haematol 2010; 151:387-396.
18. Pizzolo G, Vinante F, Chilosi M, et al. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage. Br J Haematol 1990; 75:282-284. (Pubitemid 20185473)
19. Gause A, Pohl C, Tschiersch A, et al. Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease. Blood 1991; 77:1983-1988.
20. Nadali G, Vinante F, Ambrosetti A, et al. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J Clin Oncol 1994; 12:793-797. (Pubitemid 24110920)
21. Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol 1998; 10:457-470. (Pubitemid 28564375)
22. Younes A, Kadin ME. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 2003; 21:3526-3534. (Pubitemid 46594087)
23. de Bruin PC, Gruss HJ, van der Valk P, et al. CD30 expression in normal and neoplastic lymphoid tissue: biological aspects and clinical implications. Leukemia 1995; 9:1620-1627.
24. Durkop H, Foss HD, Eitelbach F, et al. Expression of the CD30 antigen in nonlymphoid tissues and cells. J Pathol 2000; 190:613-618. (Pubitemid 30164492)
25. Younes A, Consoli U, Zhao S, et al. CD30 ligand is expressed on resting normal and malignant human B lymphocytes. Br J Haematol 1996; 93:569-571. (Pubitemid 26168602)
26. Younes A, Consoli U, Snell V, et al. CD30 ligand in lymphoma patients with CD30\+ tumors. J Clin Oncol 1997; 15:3355-3362. (Pubitemid 27485855)
27. Pinto A, Aldinucci D, Gloghini A, et al. Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood 1996; 88:3299-3305. (Pubitemid 26365562)
28. Gruss HJ, Pinto A, Gloghini A, et al. CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues. Am J Pathol 1996; 149:469-481. (Pubitemid 26256335)
29. Gattei V, Degan M, Gloghini A, et al. CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. Blood 1997; 89:2048-2059. (Pubitemid 27132121)
30. Falini B, Bolognesi A, Flenghi L, et al. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 1992; 339:1195-1196.
31. Younes A, Aggarwall BB. Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. Cancer 2003; 98:458-467. (Pubitemid 36885984)
32. Pizzolo G, Vinante F, Morosato L, et al. High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS. Aids 1994; 8:741-745. (Pubitemid 24163414)
33. Fattovich G, Vinante F, Giustina G, et al. Serum levels of soluble CD30 in chronic hepatitis B virus infection. Clin Exp Immunol 1996; 103:105-110. (Pubitemid 26027380)
34. Giacomelli R, Cipriani P, Lattanzio R, et al. Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease. Clin Exp Immunol 1997; 108:42-46. (Pubitemid 27140328)
35. Bartlett NL, Younes A, Carabasi MH, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30\+ hematologic malignancies. Blood 2008; 111:1848-1854. (Pubitemid 351451492)
36. Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007; 25:2764-2769. (Pubitemid 47123185)
37. Younes A. Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol 2011; 8:85-96.
38. Hammond PW, Vafa O, Jacinto J, et al. A humanized anti-CD30 monoclonal antibody, XmAbTM2513, with enhanced in vitro potency against CD30-positive lymphomas mediated by high affinity Fc-receptor binding. Blood (ASH Annual Meeting Abstracts) 2005; 106:1470.
39. Lawrence CE, Hammond PW, Zalevsky J, et al. XmAbTM2513, an Fc engineered humanized anti-CD30 monoclonal antibody, has potent in vitro and in vivo activities, and has the potential for treating hematologic malignancies. Blood (ASH Annual Meeting Abstracts) 2007; 110:2340.
40. Younes A, Zalevsky J, Blum KA, et al. Evaluation of the pharmacokinetics, immunogenicity, and safety of XmAb(R)2513 in the ongoing study XmAb2513-01: a phase 1 study of every other week xmab2513 to evaluate the safety, tolerability, and pharmacokinetics in patients with hodgkin lymphoma or anaplastic large cell lymphoma. Blood (ASH Annual Meeting Abstracts) 2008; 112:5012.
41. Blum KA, Smith M, Fung H, et al. Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: safety, pharmacokinetics (PK), immunogenicity, and efficacy. ASCO Meeting (abstracts) 2009; 27:8531.
42. Schnell R, Dietlein M, Staak JO, et al. Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol 2005; 23:4669-4678. (Pubitemid 46224069)
43. Oflazoglu E, Kissler KM, Sievers EL, et al. Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol 2008; 142:69-73. (Pubitemid 351783148)
44. Okeley NM, Miyamoto JB, Zhang X, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 2010; 16: 888-897.
45. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003; 21:778-784. (Pubitemid 36791396)
46. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363:1812-1821.
47. Bartlett N, Forero-Torres A, Rosenblatt J, et al. Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL). ASCO Meeting Abstracts 2009; 27:8500.
48. Chen RW, Gopal AK, Smith SE, et al. Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL). ASCO Meeting Abstracts 2011; 29:8031.
49. Pro B, Advani R, Brice P, et al. Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). ASCO Meeting Abstracts; 29:8032.
50. Forero-Torres A, Leonard JP, Younes A, et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009; 146:171-179.
51. Fanale M, Bartlett NL, Forero-Torres A, et al. The antibody-drug conjugate brentuximab vedotin (SGN-35) induced multiple objective responses in patients with relapsed or refractory CD30-positive lymphomas in a phase 1. weekly dosing study. Blood (ASH Annual Meeting Abstracts). 2009; 114:2731.
52. Bartlett N, Grove LE, Kennedy DA, et al. Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: a case series. ASCO Meeting Abstracts 2010; 28:8062.